12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Company News  |  Other News

Aveo Pharmaceuticals cancer news

Aveo will reduce headcount by 140 (62%) to about 86 to focus resources on clinical development of tivozanib for colorectal and breast cancer. Cuts will come from across the company. Aveo expects the restructuring to save about $190 million over the next two years and extend its cash runway to fund operations for at least two years. Last month, Aveo disclosed in an SEC filing that partner Astellas said it no longer plans to submit an MAA...

Read the full 362 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >